What is the efficacy of adalimumab (Humira) in the treatment of pediatric Crohn disease?

Updated: Oct 23, 2018
  • Author: Andrew B Grossman, MD; Chief Editor: Carmen Cuffari, MD  more...
  • Print
Answer

A study by Dziechciarz et al assessed the published evidence on the efficacy and safety of adalimumab for Crohn's disease in children. The study found that there was only low-quality evidence based mainly on case series that showed that approximately half of children with Crohn's disease on adalimumab therapy achieve remission during the first year of the therapy with reasonable safety profile. [29, 30]  

Another study by Horneff et al that included 577 pediatric patients reported a similar safety profile of adalimumab in pediatric patients with polyarticular juvenile idiopathic arthritis, enthesitis-related arthritis, psoriasis, and Crohn disease. The most common adverse events were infections which occurred in 76% of patients with Crohn disease. [41]


Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!